BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kellner S, Abbasi A, Carmi I, Heinrich R, Garin-Shkolnik T, Hershkovitz T, Giladi M, Haitin Y, Johannesen KM, Steensbjerre Møller R, Berlin S. Two de novo GluN2B mutations affect multiple NMDAR-functions and instigate severe pediatric encephalopathy. Elife 2021;10:e67555. [PMID: 34212862 DOI: 10.7554/eLife.67555] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
Number Citing Articles
1 Gale JR, Kosobucki GJ, Hartnett-Scott KA, Aizenman E. Imprecision in Precision Medicine: Differential Response of a Disease-Linked GluN2A Mutant to NMDA Channel Blockers. Front Pharmacol 2021;12:773455. [PMID: 34776984 DOI: 10.3389/fphar.2021.773455] [Reference Citation Analysis]
2 Krey I, von Spiczak S, Johannesen KM, Hikel C, Kurlemann G, Muhle H, Beysen D, Dietel T, Møller RS, Lemke JR, Syrbe S. L-Serine Treatment is Associated with Improvements in Behavior, EEG, and Seizure Frequency in Individuals with GRIN-Related Disorders Due to Null Variants. Neurotherapeutics 2022. [PMID: 34997442 DOI: 10.1007/s13311-021-01173-9] [Reference Citation Analysis]
3 Kellner S, Abbasi A, Carmi I, Heinrich R, Garin-Shkolnik T, Hershkovitz T, Giladi M, Haitin Y, Johannesen KM, Steensbjerre Møller R, Berlin S. Two de novo GluN2B mutations affect multiple NMDAR-functions and instigate severe pediatric encephalopathy. Elife 2021;10:e67555. [PMID: 34212862 DOI: 10.7554/eLife.67555] [Cited by in F6Publishing: 1] [Reference Citation Analysis]